Of particular interest in developing therapies that capitalize on aberrant tumor metabolism is collateral deletion of the evolutionarily conserved metabolic enzyme methylthioadenosine phosphorylase (encoded by MTAP). This evidence concerns the gene MTAP and neoplasm.